The impact of Covid-19 on ISRG has mostly been negative, if not uncertain. ISRG notes in its latest earnings release that it experienced a significant decline in procedure volume and postponements of system placements in the latter half of March in the US and Western Europe as healthcare systems in those areas diverted resources to meet the increasing demands of managing Covid-19. However, ISRG’s management is confident it is well-positioned financially and organisationally to weather the pandemic through its five-pronged financial plan which covers customer financing flexibility, employee welfare policies, securing supply chain resources, reduction of ineffective spending and protecting shareholder interest.
Intuitive Surgical: -0.3%
SINGAPORE (June 26): Nasdaq-listed Intuitive Surgical (ISRG) develops, manufactures and markets robotic-assisted systems that help empower doctors and hospitals to make surgeries less invasive. To recap, ISRG’s key innovations are the Da Vinci Surgical System and the recently-approved Ion Endoluminal System last year, which generate recurring revenue through its sales and from operating leases. Although ISRG registered a 0.3% loss for the six-month period, it still outperformed the other three benchmark indices, Dow Jones, S&P 500 and MSCI US which lost 9.7%, 5.2% and 4.7% respectively.
